Oculis Holding AG OCS 深 滬
交易中 03-26 10:28:59 美东时间
24.96
-0.040
-0.16%
華盛通- 最 高25.11
- 今 開24.81
- 成交量 9596股
- 最 低 24.78
- 昨 收 25.00
- 總市值 14.47亿
- 52周最高 30.68
- 市盈率 靜 --
- 換手率 0.02%
- 52周最低 14.00
- 委 比 98.13%
- 總股本 5798.44万
- 歷史最高 30.68
- 量 比 0.28
- 振 幅 1.32%
- 歷史最低 6.26
- 每 手 1
- 風險率 3.69%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
Oculis Holding AG announced the presentation of Phase 2 ACUITY trial results for Privosegtor at the NANOS 2026 Annual Meeting, showcasing significant improvements in low-contrast visual acuity and neuroprotective effects in patients with optic neuritis (ON). Privosegtor, a novel peptoid small molecule, has the potential to become the first neuroprotective therapy for ON, with Breakthrough Therapy designation from the FDA. The trial results highli...
03-16 09:00
美股大行评级 | 最高582美元！博通获多家机构上调目标价；GENI、Okta、Rigetti Computing、Veeva Systems、Wix.com遭多家机构下调目标价
今日重点评级关注：韦德布什：维持TScan Therapeutics"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持莱斯康制药"买入"评级，目标价从4美元升至6美元
03-06 11:58
美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价
今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元
03-05 13:56
Oculis to Participate in Upcoming Investor Conferences
Oculis Holding AG announced its participation in upcoming investor conferences in March, highlighting its late-stage pipeline and key products: Privosegtor granted breakthrough therapy designation for optic neuritis, OCS-01 with expected Q2 2026 results in diabetic macular edema, and Licaminlimab targeting precision medicine in dry eye disease. The company aims to advance as a leader in neuro-ophthalmology and ophthalmology with a strong financia...
03-05 09:00
Needham Maintains Buy on Oculis Holding, Raises Price Target to $40
Needham analyst Serge Belanger maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the price target from $36 to $40.
03-04 20:03
Oculis Holding Q4 EPS $(0.42) Beats $(0.43) Estimate
Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 37.31 percent increase over losses of $(0.67) per share from the
03-04 05:13
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update
Oculis Holding AG reported significant achievements in 2025, including clinical progress across its late-stage portfolio and a strategic expansion into neuro-ophthalmology. The company highlighted breakthrough therapy designation for Privosegtor in optic neuritis, Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema (DME), and the initiation of Licaminlimab's genotype-based registrational trial for dry eye disease (DED). Cash reserves reac...
03-03 21:05
Oculis Appoints Katie Kazem as Chief Legal Officer
Oculis Holding AG has appointed Katie Kazem as Chief Legal Officer, enhancing its leadership to advance three late-stage assets toward clinical milestones. Kazem, with over 15 years of experience in corporate governance and securities law, previously served as external legal counsel to Oculis. Her expertise will support the company’s progress in developing innovative therapies for neuro-ophthalmology and ophthalmology, including Privosegtor’s PIO...
02-17 09:00
Oculis Holding shares are trading higher after the FDa granted the company's neuroprotective candidate Privosegtor breakthrough therapy designation.
Oculis Holding shares are trading higher after the FDa granted the company's ne...
01-06 22:15
美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
2025-12-22 15:05
